Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on 'Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting'

MLA

Antonio Bertoletti, and Anthony T Tan. “Engineering HBV-Specific T Cells for the Treatment of HBV-Related HCC and HBV Infection: Past, Present, and Future. Editorial on ‘Genetically-Modified, Redirected T Cells Target Hepatitis B Surface Antigen-Positive Hepatocytes and Hepatocellular Carcinoma Lesions in a Clinical Setting.’” Clinical and Molecular Hepatology, vol. 30, no. 4, Oct. 2024, pp. 728–34. EBSCOhost, https://doi.org/10.3350/cmh.2024.0469.

APA

Antonio Bertoletti, & Anthony T Tan. (2024). Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.” Clinical and Molecular Hepatology, 30(4), 728–734. https://doi.org/10.3350/cmh.2024.0469

Chicago

Antonio Bertoletti, and Anthony T Tan. 2024. “Engineering HBV-Specific T Cells for the Treatment of HBV-Related HCC and HBV Infection: Past, Present, and Future. Editorial on ‘Genetically-Modified, Redirected T Cells Target Hepatitis B Surface Antigen-Positive Hepatocytes and Hepatocellular Carcinoma Lesions in a Clinical Setting.’” Clinical and Molecular Hepatology 30 (4): 728–34. doi:10.3350/cmh.2024.0469.